Glaukos Q1 Sales Jump 41%, Beats Estimates, Lifts Full-Year Outlook
summarizeSummary
Glaukos Corp reported strong first-quarter results, with net sales surging 41% year-over-year to $150.6 million, significantly exceeding analyst expectations of $136.9 million. The company also narrowed its adjusted net loss to $10.4 million, beating the consensus estimate of a $16.96 million loss. Following this robust performance, Glaukos raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. This positive revision is driven by strong growth in its glaucoma segment, particularly in the U.S., and the performance of key products like iDose TR and Epioxa. This news is a material positive catalyst, indicating strong operational momentum and improved profitability outlook, which should be well-received by investors.
At the time of this announcement, GKOS was trading at $116.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $73.16 to $130.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.